López GR, Benítez RA, Pérez SA, Díaz MB, Mejía RLC

Language: Spanish
References: 13
Page: 45-50
PDF size: 436.90 Kb.

ABSTRACT

Background: Osteoarthritis is the most prevalent musculoskeletal condition among the population. Knee osteoarthritis is either primary or secondary. Hyaluronic acid is a polysaccharide of high molecular weight component of synovial fluid and cartilage. Viscosupplementation is the administration of preparations of hyaluronate in the knee.
Patients and method: A retrospective, observational, longitudinal and descriptive study done in male and female patients who were submitted to viscosupplementation with Synvisc at the external consultation of Regional Hospital General Ignacio Zaragoza, from September of 2011 to April of 2012. We applied three weekly doses and applied VAS and WOMAC functional scale before infiltration, after infiltration, at three and six months.
Results: 41 knees of 35 patients were infiltrated, corresponding to 6 men (17.1%) and 29 women (82.9%), with a 1:5 ratio, with an average age of 60 years. The average results for visual analogue scale were: 8.5 points before infiltration, 6.3 points after infiltration, 4.7 points at 3 months and 4.5 points at 6 months. For the scale of WOMAC were: 62.1 points before infiltration, 29.1 points after infiltration, 29.5 points at three months and 30.9 points at six months.
Conclusion: Patients reported improvement in 90% and only 10% reported no improvement. It was observed symptoms relief at the end of treatment, which, although unobtrusive, supports this option as conservative management in patients with knee osteoarthrosis.

REFERENCES

1. Alonso-Carro G, Villanueva-Blaya P. Aplicaciones clínicas y efectos terapéuticos de la viscosuplementación en la artrosis de rodilla. Rev Ortop Traumatol 2002;5:458-464.

2. Sinusas K. Osteoarthritis: diagnosis and treatment. Am Fam Physician 2012;85:49-56.

3. Conrozier T, Jerosch J, Beks P, Kemper F, et al. Prospective, multi-center, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study. Arch Orthop Trauma Surg 2009;129:417-423.

4. Ringdahl E, Pandit S. Treatment of knee osteoarthritis. Am Fam Physician 2011;83(11):1287-1292.

5. Shu-Fen Sun, Yi-Jion Chou, Chien-Wei Hsu, Wen-Ling Chen. Hyaluronic acid as a treatment for ankle osteoarthritis. Curr Rev Musculoskelet Med 2009;2:78-82.

6. Sierra-Merlano RM, Salas Slado JA. Tratamiento local de la osteoartritis de cadera, rodilla y mano. Rev Colomb Reumatol 2002;9(1):25-27.

7. Álvarez-López A, García-Lorenzo Y, Mariño-Fonseca J. Tratamiento conservador de la osteoartritis de rodilla. Rev Cubana Ortop Traumatol 2004;18(1);47-52.

8. Harvey WF, Hunter DJ. Pharmacologic intervention for osteoarthritis in older adults. Clin Geriatr Med 2010;26:503- 515.

9. Harvey WF, Hunter DJ. The role of analgesics and intraarticular injections in disease management. Rheum Dis Clin North Am 2008;34:777-788.

10. Pérez-Serna AG, Negrete-Corona J, Chávez-Hinojosa E, López-Mariscal C. Efectividad del hialuronato de sodio en pacientes con gonartrosis, estudio comparativo y aleatorizado. Acta Ortop Mex 2011;25:208-215.

11. van den Bekerom, Rys B, Mulier M. Viscosupplementation in the hip: evaluation of hyaluronic acid formulations. Arch Orthop Trauma Surg 2008;28:275-280.

12. Wang Y, Hall S, Hanna F, Wluka AE, et al. Effects of hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculoskelet Disord 2011;12:195.

13. Polach-Vengud J, Selva-Otaolaurruchi J, Cortes-Botella J, García-Salom P, García-Mosalve A. Viscosuplementación: Revisión de los diferentes hialuronatos en España. Farm Hosp 2000;24:371-376.